肾移植受者对非mRNA SARS-CoV-2疫苗的抗体应答
该研究纳入2022年2月至4月在一家三级移植门诊随访的224例肾移植受者,检测SARS-CoV-2刺突蛋白IgG抗体。197例(87.94%)检出抗体,中位滴度307.5 AU/ml,75.9%达中和范围。接种时患糖尿病与抗体应答较差相关,接种Covishield™较Covaxin™抗体应答更高。
要点
- 224例肾移植受者中197例(87.94%)检出S1/S2 IgG抗体,中位滴度307.5 AU/ml。
- 170/224(75.9%)受者抗体滴度达中和范围。
- 接种时糖尿病与较差抗体应答相关(aOR 0.31,95%CI -0.10至0.90,p=0.032)。
核心结论
- 肾移植受者接种非mRNA SARS-CoV-2疫苗后显示良好的抗体应答。
- 糖尿病和移植肾功能异常与较差的血清转化率相关。
研究设计与样本
- 研究纳入2022年2月至4月期间在一家三级移植门诊随访的肾移植受者。
- 采用化学发光免疫分析法检测SARS-CoV-2刺突蛋白IgG抗体滴度。
- 收集人口学、临床和实验室特征,并按既往COVID-19感染史和疫苗接种剂次对患者分类。
- 使用多变量回归分析获取抗体应答的预测因素。
主要发现
- 224例肾移植受者中197例(87.94%)检出S1/S2 IgG抗SARS-CoV-2抗体,中位[IQR]滴度为307.5 AU/ml [91 AU/ml至400 AU/ml]。
- 170/224(75.9%)受者抗体滴度达中和范围。
- 接种时糖尿病与较差抗体应答相关(aOR 0.31,95%CI -0.10至0.90,p=0.032)。
- 接种Covishield™(ChAdOx1 nCoV-19重组冠状病毒疫苗)较Covaxin™(BBV152)抗体应答更高(aOR 5.04,95%CI 1.56至16.22,p=0.007)。
- 基线时移植肾功能异常与较差抗体应答相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Kidney transplant recipients (KTRs) show poor antibody response to the SARS-CoV-2 vaccine. There is limited data on immune response to non-mRNA vaccines in KTRs. We studied the antibody response to the SARS-CoV-2 non-mRNA vaccine in a cohort of kidney transplant recipients. METHODS: We included KTRs following up in the tertiary care transplant outpatient clinic from February to April 2022. SARS-CoV-2 spike protein IgG antibody titers were measured using chemiluminescence immunoassay. Data on demographic, clinical, and laboratory characteristics were collected, and patients were characterized by the history of Coronavirus disease 2019 (COVID-19) infection in the past and the number of vaccine doses received. Predictors of antibody response were obtained using multivariate regression analysis. RESULTS: S1/S2 IgG anti-SARS-CoV-2 antibodies were detected in 197 (87.94%) of 224 KTRs with a median [IQR] titers of 307.5 AU/ml [91 AU/ml - 400 AU/ml]. Neutralizing range antibody titers were found in 170/224 (75.9%) KTRs. Diabetes at the time of vaccination was associated with poorer antibody response (aOR 0.31, 95% confidence interval [CI] - 0.10, 0.90; p = 0.032) and vaccination with Covishield™ (ChAdOx1 nCoV- 19 Recombinant CoronaVirus Vaccine) showed higher antibody response as compared to Covaxin™ (BBV152) (aOR 5.04, 95% CI - 1.56, 16.22; p = 0.007). Graft dysfunction at baseline was associated with poorer antibody response. CONCLUSIONS: KTRs showed good antibody response after SARS-CoV-2 vaccination with non-mRNA vaccines. Diabetes and graft dysfunction were associated with poor seroconversion rates.
引用
- Bajpai D, Bose S, Saxena N, et al. Antibody response to non-mRNA SARS-CoV-2 vaccine in kidney transplant recipients. Vaccine. 2024. PMID: 39122634. doi:10.1016/j.vaccine.2024.126206
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。